RecruitingNot ApplicableNCT07260942
Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
Sponsor
University Hospital, Bordeaux
Enrollment
120 participants
Start Date
Apr 21, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- age ≥ 18 years;
- diagnosis of systemic lupus erythematosus;
- being affiliated to health insurance, willing to participate and to sign informed consent;
- control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease.
Exclusion Criteria2
- pregnant or breastfeeding women;
- patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALblood sample
30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07260942
Related Trials
Anifrolumab Malignancy and Serious Infections Study
NCT070001104 locations
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT047513961 location
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
NCT069777247 locations
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
NCT073635909 locations
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325227 locations